RALLYBIO CORP (RLYB) Stock Overview
USA - NASDAQ:RLYB - US75120L1008 - Common Stock
RLYB Key Statistics, Chart & Performance
The current stock price of RLYB is 0.5886 USD. In the past month the price decreased by -0.91%. In the past year, price decreased by -46.49%.
RLYB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.01 | 393.01B | ||
| AMGN | AMGEN INC | 13.09 | 153.65B | ||
| GILD | GILEAD SCIENCES INC | 14.74 | 141.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.62 | 98.23B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.97 | 62.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.45B | ||
| ARGX | ARGENX SE - ADR | 79.48 | 45.09B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.84 | 39.75B | ||
| INSM | INSMED INC | N/A | 30.60B | ||
| NTRA | NATERA INC | N/A | 24.86B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.13B | ||
| BIIB | BIOGEN INC | 8.9 | 20.89B |
Related stock screener links
About RLYB
Company Profile
Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut and currently employs 25 full-time employees. The company went IPO on 2021-07-29. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Company Info
RALLYBIO CORP
234 Church Street, Suite 1020
New Haven CONNECTICUT US
CEO: Martin W. Mackay
Employees: 20
Phone: 12038593820
RALLYBIO CORP / RLYB FAQ
What is the stock price of RALLYBIO CORP today?
The current stock price of RLYB is 0.5886 USD. The price decreased by -1.77% in the last trading session.
What is the ticker symbol for RALLYBIO CORP stock?
The exchange symbol of RALLYBIO CORP is RLYB and it is listed on the Nasdaq exchange.
On which exchange is RLYB stock listed?
RLYB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RALLYBIO CORP stock?
10 analysts have analysed RLYB and the average price target is 1.02 USD. This implies a price increase of 73.29% is expected in the next year compared to the current price of 0.5886. Check the RALLYBIO CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RALLYBIO CORP worth?
RALLYBIO CORP (RLYB) has a market capitalization of 24.60M USD. This makes RLYB a Nano Cap stock.
How many employees does RALLYBIO CORP have?
RALLYBIO CORP (RLYB) currently has 20 employees.
What are the support and resistance levels for RALLYBIO CORP (RLYB) stock?
RALLYBIO CORP (RLYB) has a support level at 0.58 and a resistance level at 0.61. Check the full technical report for a detailed analysis of RLYB support and resistance levels.
Is RALLYBIO CORP (RLYB) expected to grow?
The Revenue of RALLYBIO CORP (RLYB) is expected to decline by -19.74% in the next year. Check the estimates tab for more information on the RLYB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy RALLYBIO CORP (RLYB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RLYB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RLYB, evaluating the profitability, health, valuation and growth aspects
- RALLYBIO CORP (RLYB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RALLYBIO CORP (RLYB) Sales and EPS estimates to see what analysts future expectations are.
- RALLYBIO CORP (RLYB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RALLYBIO CORP (RLYB) Insider and Institutional Ownership to learn about the owners and their transactions.
- RALLYBIO CORP (RLYB) Stock Chart to make your own analysis
- RALLYBIO CORP (RLYB) Latest news and press-releases to stay up to date.
Does RALLYBIO CORP (RLYB) stock pay dividends?
RLYB does not pay a dividend.
What is the Price/Earnings (PE) ratio of RALLYBIO CORP (RLYB)?
RALLYBIO CORP (RLYB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.94).
What is the Short Interest ratio of RALLYBIO CORP (RLYB) stock?
The outstanding short interest for RALLYBIO CORP (RLYB) is 1.65% of its float. Check the ownership tab for more information on the RLYB short interest.
RLYB Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to RLYB. When comparing the yearly performance of all stocks, RLYB is one of the better performing stocks in the market, outperforming 80.17% of all stocks.
RLYB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RLYB. RLYB has a great financial health rating, but its profitability evaluates not so good.
RLYB Financial Highlights
Over the last trailing twelve months RLYB reported a non-GAAP Earnings per Share(EPS) of -0.94. The EPS increased by 47.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.67% | ||
| ROE | -90.62% | ||
| Debt/Equity | 0 |
RLYB Forecast & Estimates
10 analysts have analysed RLYB and the average price target is 1.02 USD. This implies a price increase of 73.29% is expected in the next year compared to the current price of 0.5886.
For the next year, analysts expect an EPS growth of 35.78% and a revenue growth -19.74% for RLYB